- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00885950
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
February 3, 2014 updated by: Maastricht University Medical Center
Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants
The purpose of the study is to determine whether anticoagulant use (i.e.
salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome secondary to oxaliplatin-based neoadjuvant chemotherapy in patients suffering from colorectal liver metastases.
Study Overview
Status
Completed
Detailed Description
Surgical resection remains the only curative treatment for patients suffering from colorectal liver metastases, but only 15-25% of patients are initially eligible for resection.
The majority of patients suffering from colorectal liver metastases receives chemotherapy prior to liver surgery in order to downsize the colorectal liver metastases.
Preoperative treatment with oxaliplatin-based chemotherapy is related to sinusoidal injury, the so-called sinusoidal obstruction syndrome.
Patients with histologically proven sinusoidal injury undergoing liver surgery have a higher risk of post-resectional morbidity.
Damage to the hepatic sinusoids is a key factor for the development of the sinusoidal obstruction syndrome.
Anticoagulants (i.e.
salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) might be able to prevent this damage and, consequently, the development of the sinusoidal obstruction syndrome in patients suffering from colorectal liver metastases treated with neoadjuvant chemotherapy.
Study Type
Observational
Enrollment (Actual)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Maastricht, Netherlands
- Department of Surgery; Maastricht University Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients suffering from colorectal liver metastases who have undergone a partial hepatic resection
Description
Inclusion Criteria:
- age > 18 years
- colorectal liver metastases that are eligible for resection
- operated from January 2008 up until December 2009 at Maastricht University Medical Centre
Exclusion Criteria:
- irresectable colorectal liver metastases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Colorectal liver metastases
Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Histologically proven hepatic sinusoidal injury
Time Frame: during liver surgery
|
during liver surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
90-day morbidity and mortality
Time Frame: up until 90 days after surgery
|
up until 90 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Steven WM Olde Damink, MD, PhD, MSc, Maastricht University Medical Centre
- Principal Investigator: Rob Jansen, MD, PhD, Maastricht University Medical Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
April 21, 2009
First Submitted That Met QC Criteria
April 21, 2009
First Posted (Estimate)
April 22, 2009
Study Record Updates
Last Update Posted (Estimate)
February 4, 2014
Last Update Submitted That Met QC Criteria
February 3, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-4-076
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Liver Metastases
-
Humanitas Clinical and Research CenterCompletedColorectal Cancer | Liver Metastases | Immunotherapy | Colorectal Liver Metastases
-
Mayo ClinicRecruitingColorectal Cancer | Colorectal Liver MetastasesUnited States
-
Shanghai Changzheng HospitalNot yet recruiting
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Completed
-
Fudan UniversityNot yet recruitingColorectal Cancer Liver MetastasesChina
-
Fudan UniversityUnknown
-
Vastra Gotaland RegionRecruitingColorectal Cancer | Liver Metastases | Colorectal Liver MetastasesSweden
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Liver Metastases | RegorafenibChina
-
Ye XuUnknownResected Liver Metastases From Colorectal CancerChina
-
Society of Interventional OncologyRecruitingColorectal Liver MetastasesUnited States, Netherlands, Greece